Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab in minority participants with relapsing multiple sclerosis
PACTR202103563404333Phase 4Recruiting
- Sponsor
- Genentech
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of ocrelizumab, sponsored by Genentech. Started Jul 2020; status: recruiting.
02
Drugs
ocrelizumab
Beyond the preview
Go deeper on PACTR202103563404333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202103563404333.